Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2021-04-06 Capital/Financing Update
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Appendix 2A - Exercise of Employee Options 15 pages 198.4KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX. It includes detailed information about the entity, the type of securities being quoted, and the circumstances of the issue. This type of document is a regulatory announcement related to capital markets activity, specifically the issuance and quotation of new securities. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement or certification. The document fits the category of Capital/Financing Update (CAP) because it provides updates on the company's capital structure changes and securities issuance.
2021-04-06 English
Investor Presentation 30 pages 3.3MB
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation | April 2021' and contains detailed information about the company's drug development pipeline, clinical trials, management team, and strategic outlook. It includes forward-looking statements, descriptions of clinical programs, scientific leadership, and detailed drug development plans. There are no financial statements or regulatory certifications, nor is it a brief announcement or voting result. The content is consistent with a detailed presentation aimed at investors, focusing on financials, strategy, and market position rather than a formal report or regulatory filing. Therefore, the document fits the category of an Investor Presentation (IP).
2021-04-06 English
Clinical Trial of Treatment to Prevent Wound and Burns Scars 3 pages 133.1KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 31 March 2021 from Pharmaxis Ltd announcing the commencement of a world-first clinical trial for a new drug treatment to prevent wound and burn scars. It contains no financial statements, no detailed financial performance data, no regulatory certifications, no voting results, no management or board changes, no capital or financing updates, and no earnings information. The content is focused on a clinical trial announcement and company research progress, typical of a press release or media announcement. The document length is 7442 characters, which is relatively short and consistent with a media release rather than a full report. There is no indication that this is an Annual Report, Interim Report, Earnings Release, or any other formal financial or regulatory filing. Therefore, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2021-03-30 English
US Commercial Launch of Bronchitol 2 pages 103.2KB
Capital/Financing Update Classification · 85% confidence The document is a media release announcing the commercial launch of a pharmaceutical product (Bronchitol) in the US market, milestone payments received, and publication of clinical trial data. It contains no financial statements, regulatory filings, or detailed financial performance data. It is a corporate announcement related to product commercialization and milestone payments, which aligns with updates on company fundraising, financing activities, or capital structure changes. Therefore, the document fits best under Capital/Financing Update (CAP). The document length is 4356 characters, which is short but contains substantive information about milestone payments and commercial launch, not just a brief announcement or report publication. Hence, it is not RPA or RNS.
2021-03-18 English
First Patient Enrolled - Clinical Trial for Cancer Treatment 3 pages 137.0KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 22 February 2021 from Pharmaxis Ltd announcing the enrollment of the first patient in a clinical trial for a new cancer treatment drug PXS-5505. It details the trial design, endpoints, and locations, and provides background on the company and the disease myelofibrosis. There are no financial statements, earnings data, or regulatory filings such as 10-K or interim reports. The document is an announcement of a clinical trial commencement, which is a corporate update related to research and development progress rather than financial or governance reporting. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a regulatory filing or certification. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2021-02-21 English
Appendix 2A - Exercise of Employee Options 15 pages 198.4KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form submitted to the ASX (Australian Securities Exchange) for the application for quotation of securities. It includes details about the entity, the type of securities being quoted, and compliance with ASX Listing Rules. This type of document is a regulatory announcement related to securities issuance and quotation, not a financial report, earnings release, or management discussion. It is a formal regulatory filing notifying the market of securities quotation and issuance details. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement but a detailed regulatory form, yet it is not a financial report or other specific category.
2021-02-14 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.